3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells

(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Vital, Patrik da Silva, Bonatelli, Murilo, Dias, Marina Pereira, de Salis, Larissa Vedovato Vilela, Pinto, Mariana Tomazini, Baltazar, Fátima, Maria-Engler, Silvya Stuchi, Pinheiro, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779063/
https://www.ncbi.nlm.nih.gov/pubmed/36555289
http://dx.doi.org/10.3390/ijms232415650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779063/
https://www.ncbi.nlm.nih.gov/pubmed/36555289
http://dx.doi.org/10.3390/ijms232415650

Ejemplares similares